The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay - European Medical Journal
×

Browse

The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay

|
Oncology

The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk categories in relation to the likelihood of breast cancer recurrence. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses adjuvant treatment decisions in early breast cancer patients with intermediate Oncotype DX RS results.

This content is supported by Genomic Health, Inc.